Cantor’s Elemer Piros waits for pass-through reimbursement to be address, before joining the ‘Omeros party’.
Omeros Corporation (NASDAQ:OMER) shares are on fire this evening, rising nearly 11%, after the drug maker reported better-than-expected 3Q Omidria sales. Third Quarter Highlights 3Q …
Omeros Corporation (NASDAQ:OMER) announced that extended follow-up data from patients with immunoglobulin A (IgA) nephropathy treated with OMS721 were presented on November 4, 2017 at …
Jason Kolbert believes that OMER’s OMS721 flashes an upper hand over competitor Soliris drug.
Omeros Corporation (NASDAQ:OMER) announced further positive data from its ongoing Phase 2 study of OMS721 evaluating patients with hematopoietic stem cell transplant-associated thrombotic …
Omeros Corporation (NASDAQ:OMER) announced the presentation of a case report of a patient having co-existing hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA) and …
Drug maker Omeros Corporation (NASDAQ:OMER) announced that it entered into a settlement agreement with Par Pharmaceutical and its subsidiary Par Sterile Products, resolving …
Analyst Cautiously Celebrating Biotech Player’s Stellar Q2 Performance from the Sidelines
Omeros Corporation (NASDAQ:OMER) announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2017, which include: 2Q …
Omeros Corporation (NASDAQ:OMER) announced that OMS721 has received orphan drug designation from the FDA for the treatment of Immunoglobulin A (IgA) nephropathy. OMS721 is Omeros’ …
